Immune‐independent acquired resistance to PD‐L1 antibody initiated by PD‐L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib

Authors: Yuan Gao, Yingfang Feng, Shaochuan Liu, Yan Zhang, Jing Wang, Tingting Qin, Peng Chen, Kai Li

Source: Cancer Medicine, Vol 12, Iss 14, Pp 15337-15349 (2023)

Subject Terms: anlotinib, drug resistance, melanoma, PD‐L1, PI3K/AKT, VECs, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/5e4f24d28b8f47bebf4b9cfb70eefde3

Multiomics profiling reveals the benefits of gamma-delta (γδ) T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer

Authors: Xiaofeng Wang, Chen Li, Jie Chen, Zhiqiang Wu, Zhen Zhang, Junyi Li, Lu Yu, Yong Guan, Yuhan Zhang, Yuanjie Cao, Yancheng Liu, Hui Bai, Shaochuan Liu, Miaomiao Gao, Chenglu Lu, Zhen Tao, Zhiyong Yuan

Source: Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://jitc.bmj.com/content/12/1/e008355.full; https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/fc82d0ec90a245cd9013c965b5115511

Novel strategies for cancer immunotherapy: counter-immunoediting therapy

Authors: Shaochuan Liu, Qian Sun, Xiubao Ren

Source: Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-37 (2023)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1756-8722

Access URL: https://doaj.org/article/546a8c5a4e54411abe3d3fef81652166

CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer

Authors: Shaochuan Liu, Yuan Meng, Liang Liu, Yingge Lv, Wenwen Yu, Ting Liu, Limei Wang, Di Mu, Qiuru Zhou, Min Liu, Yulin Ren, Dong Zhang, Baihui Li, Qian Sun, Xiubao Ren

Source: Cell Death and Disease, Vol 13, Iss 5, Pp 1-12 (2022)

Subject Terms: Cytology, QH573-671

File Description: electronic resource

Relation: https://doaj.org/toc/2041-4889

Access URL: https://doaj.org/article/509f6e73170d4b0ea79f16214ad328c6

Molecular subtypes based on CNVs related gene signatures identify candidate prognostic biomarkers in lung adenocarcinoma

Authors: Baihui Li, Ziqi Huang, Wenwen Yu, Shaochuan Liu, Jian Zhang, Qingqing Wang, Lei Wu, Fan Kou, Lili Yang

Source: Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 7, Pp 704-717 (2021)

Subject Terms: Molecular subtypes, CNVs, Prognostic biomarkers, LUAD, TROAP, RASGRF1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S1476558621000312; https://doaj.org/toc/1476-5586

Access URL: https://doaj.org/article/2013cf868ed2411b8d490483f357e722

Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling

Authors: Tingting Qin, Zhujun Liu, Jing Wang, Junling Xia, Shaochuan Liu, Yanan Jia, Hailin Liu, Kai Li

Source: Cancer Biology & Medicine, Vol 17, Iss 3, Pp 753-767 (2020)

Subject Terms: anlotinib, vegfr-3 dephosphorylation, lymphangiogenesis, lymph node metastasis, lung adenocarcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.cancerbiomed.org/index.php/cocr/article/view/1681; https://doaj.org/toc/2095-3941

Access URL: https://doaj.org/article/143d138746924465820daa89f90a08f0

Clinical importance of VEGFC and PD‐L1 co‐expression in lung adenocarcinoma patients

Authors: Tingting Qin, Junling Xia, Shaochuan Liu, Jing Wang, Hailin Liu, Yan Zhang, Yanan Jia, Kai Li

Source: Thoracic Cancer, Vol 11, Iss 5, Pp 1139-1148 (2020)

Subject Terms: Lung adenocarcinoma, overall survival, PD‐L1, progression‐free survival, VEGFC, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1759-7706; https://doaj.org/toc/1759-7714

Access URL: https://doaj.org/article/85fb93f4343548b1bca9e01b4a19f246

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab

Authors: Zhujun Liu, Tingting Qin, Xiaohan Yuan, Jie Yang, Wei Shi, Xiaoling Zhang, Yanan Jia, Shaochuan Liu, Jing Wang, Kai Li

Source: Frontiers in Oncology, Vol 12 (2022)

Subject Terms: anlotinib abrogated bevacizumab resistance, anlotinib, bevacizumab, MMP2, N-cadherin, RGC32, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2022.875888/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/c628db07eb0448a1a3002053d10dd353

PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival

Authors: Shaochuan Liu, Tingting Qin, Yanan Jia, Kai Li

Source: Frontiers in Oncology, Vol 9 (2019)

Subject Terms: PD-L1, VEGFA, overall survival, progression-free survival, lung adenocarcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/article/10.3389/fonc.2019.00189/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/d9c823252a2249e4ba599f4ddede8285